Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

U.S. Food, Drug & Cosmetic Act (FDCA) allows the Food and Drug Administration (FDA) to approve a follow-on drug on the basis of data in the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms. To the extent a Section 505(b)(2) applicant is relying on the FDA's findings for an already-approved drug, the applicant is required to certify to the FDA concerning any patents listed for the approved drug in the FDA's Orange Book publication, which may include a certification that listed patents are invalid or will not be infringed by the manufacture, use or sale of the new drug.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015   Cynosure, Inc. (Nasdaq: CYNO ... aesthetic procedures and precision surgical applications worldwide, today reported ... 2015. First-Quarter Highlights: , North America ... earnings of $0.15 per share; GAAP earnings break-even ... 31, 2015 "Cynosure delivered 21 percent year-over-year ...
(Date:5/5/2015)...  Astellas announced that two abstracts detailing clinical data ... data from a study of mirabegron as an add-on ... breaking plenary session at the 2015 annual meeting of ... New Orleans, Louisiana . ... to evaluate enzalutamide compared to bicalutamide in metastatic prostate ...
(Date:5/5/2015)... 5, 2015  AMRI (NASDAQ: AMRI ) today reported ... 31, 2015. Highlights: , First quarter ... , First quarter royalties of $6.7 million, down ... diluted EPS of $0.20 up 25% from $0.16 in 2014, ... current quarter , Completed the acquisitions of ...
Breaking Medicine Technology:Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 2Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 3Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 4Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 5Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 6Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 7Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 8Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 9AMRI Announces First Quarter 2015 Results 2AMRI Announces First Quarter 2015 Results 3AMRI Announces First Quarter 2015 Results 4AMRI Announces First Quarter 2015 Results 5AMRI Announces First Quarter 2015 Results 6AMRI Announces First Quarter 2015 Results 7AMRI Announces First Quarter 2015 Results 8AMRI Announces First Quarter 2015 Results 9AMRI Announces First Quarter 2015 Results 10AMRI Announces First Quarter 2015 Results 11AMRI Announces First Quarter 2015 Results 12AMRI Announces First Quarter 2015 Results 13AMRI Announces First Quarter 2015 Results 14AMRI Announces First Quarter 2015 Results 15AMRI Announces First Quarter 2015 Results 16
... SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin Board: ... that the Company has made a technological breakthrough in the ... which are tiny glass substrates that contain rows and columns ... The advance allows highly precise printing of as many as ...
... , NEW YORK, Dec. 22 Delcath Systems, Inc. (Nasdaq: ... treatment method for primary and metastatic cancers to the liver, ... Scientific Advisory Board, effective immediately. , "We formed our ... our Delcath PHP System(TM) with insight from the leading experts ...
Cached Medicine Technology:Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 2Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 3
(Date:5/5/2015)... Sheltering Arms held its annual benefit ... and Cravath, Swaine & Moore LLP for their philanthropic ... event was co-chaired by Vanguard sponsors Morgan Stanley and ... highlighted Sheltering Arms’ significant growth in New York City ... 2015. Formerly Episcopal Social Services, Sheltering Arms has become ...
(Date:5/5/2015)... 05, 2015 Buckeye Health Plan (BHP) ... CEO and plan president of Buckeye Health Plan. Hill, ... position immediately. , Hill has more than 28 years ... Pacific Northwest, from managed care to large health care ... CEO of HealthPlus of Michigan, a health plan serving ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they will ... Ed Begley Jr., airing via Discovery Channel 3rd QTR ... will focus on NovaSom, a leader in Obstructive Sleep ... AccuSom® home sleep test, which is the only comprehensively ... and next-day test results and interpretation. , ...
(Date:5/5/2015)... After record-breaking sales of Extend Nutrition’s ... Cookies & Cream flavor at stores nationwide this month. ... raised the bar for nutritional snacks. The brand ... nutritional profile, backed by international patents and clinical studies. ... additional new products and expand retail availability throughout 2015. ...
(Date:5/5/2015)... May 05, 2015 After conducting a ... solutions firm B. E. Smith, West Holt Medical ... as chief executive officer. A skilled healthcare executive with ... assume his new duties on June 1st. , “Brad ... well as a keen understanding and success in building ...
Breaking Medicine News(10 mins):Health News:Sheltering Arms Honors Walt "Clyde" Frazier and Cravath, Swaine & Moore LLP at Annual Gala 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:West Holt Medical Services Hires New Chief Executive Officer 2Health News:West Holt Medical Services Hires New Chief Executive Officer 3
... regain pre-pregnancy body, IRVINE, Calif., Aug. ... post-baby body shaping solution VelaShape(TM),and other medical ... today reveals the results of the VelaShape ... desire to regain their,pre-pregnancy body. Syneron commissioned ...
... host roundtable discussion as part of national ... Campaign for an American Solution, SALT LAKE ... Utah small business owners at a,roundtable discussion on health care issues ... the health insurance industry,s Campaign for,an American Solution, a new national ...
... Gerianne Tringali DiPiano,President, CEO and founder of FemmePharma in ... healthcare executives and one of the top 12 entrepreneurs ... DiPiano is one of only two women., PharmaVOICE ... has not only carved out a niche in the ...
... Texas Mutual Insurance Company,(TMIC) said it would appeal ... the 14th Court of Appeals., The 14th Court ... a,district court in Harris County found TMIC acted in ... insurance code. The jury also had found,that plaintiff P. ...
... for diabetes , , WEDNESDAY, Aug. 27 (HealthDay News) -- Scientists ... insulin-producing beta cells, a feat they call an "extreme makeover." ... or even a cure for both type 1 and type ... production or uptake. , The process, reported online Aug. 27 ...
... Tacoma, Wash. August 27, 2008 Two new ... U.S. military personnel, yet the condition is frequently underdiagnosed. ... journal of the American Headache Society, examine the incidence ... 1-year combat tour in Iraq , as well as ...
Cached Medicine News:Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 3Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 4Health News:Health Insurance Industry Listens to Health Care Concerns of Utah Small Business Owners 2Health News:Health Insurance Industry Listens to Health Care Concerns of Utah Small Business Owners 3Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 2Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 3Health News:Texas Mutual Insurance to Appeal 14th Court's Decision to Texas Supreme Court 4Health News:Pancreatic Cells Turned Into Insulin-Producing Beta Cells 2Health News:Pancreatic Cells Turned Into Insulin-Producing Beta Cells 3Health News:Army personnel show increased risk for migraine 2
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: